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Plasma C-Reactive Protein and Endothelin-1 Level in Patients 
with Chronic Obstructive Pulmonary Disease and Pulmonary 
Hypertension
Pulmonary hypertension is a frequent complication of chronic obstructive pulmonary 
disease (COPD) and associated with a worse survival and increased risk of hospitalization 
for exacerbation of COPD. However, little information exists regarding the potential role of 
systemic inflammation in pulmonary hypertension of COPD. The purpose of the present 
study was to investigate the degree of C-reactive protein (CRP) and endothelin-1 (ET-1) 
levels in COPD patient with and without pulmonary hypertension. The levels of CRP and 
ET-1 were investigated in 58 COPD patient with pulmonary hypertension and 50 patients 
without pulmonary hypertension. Pulmonary hypertension was defined as a systolic 
pulmonary artery pressure (Ppa) ≥35 mmHg assessed by Doppler echocardiography. Plasma 
CRP and ET-1 levels were significantly higher in patients with pulmonary hypertension than 
in patients without hypertension. There were significant positive correlations between the 
plasma ET-1 level and CRP level in the whole study groups. For COPD patients, systolic Ppa 
correlated significantly with plasma CRP levels and plasma ET-1 levels. These findings 
support a possibility that CRP and ET-1 correlate to pulmonary hypertension in COPD 
patients. 
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INTRODUCTION
Pulmonary hypertension is a frequent complication of chronic 
obstructive pulmonary disease (COPD) and associated with a 
worse survival and increased risk of hospitalization for exacer-
bation of COPD (1, 2). Pulmonary hypertension is character-
ized by thickening of pulmonary artery walls, narrowing of pul-
monary artery lumina, and elevation of pulmonary vascular re-
sistance. These pathophysiologic findings could be explained 
by the effects of hypoxemia, shear stress, endothelial dysfunc-
tion, and inflammatory reaction (3). Alveolar hypoxia may play 
a role in the pathogenesis of pulmonary hypertension associat-
ed with COPD. However, structural and functional changes in 
the pulmonary arteries have also been observed in normoxic 
patients with mild-to-moderate COPD (4, 5). 
  Several studies (6, 7) suggested that chronic inflammation 
contribute to pulmonary vascular remodeling. C-reactive pro-
tein (CRP) has both proinflammatory and antiinflammatory 
actions. Proinflammatory effects include the induction in mono-
cytes of inflammatory cytokines and tissue factors (8, 9). In pul-
monary hypertension with COPD patients, the level of CRP cor-
relate with pulmonary artery pressure and is an independent 
predictor of systolic pulmonary artery pressure (6). 
  Endothelin-1 (ET-1) is a potent vasoconstrictor peptide pro-
duced by the vascular endothelium (10). Increased production 
of ET-1 in vascular endothelium may result in remodeling of the 
pulmonary vasculature, leading to the development of pulmo-
nary hypertension in patient with COPD. ET-1 levels are elevat-
ed in patient with pulmonary hypertension and strongly corre-
lated with disease severity (11, 12). However, Bacakoğlu et al. (13) 
reported that plasma levels of ET-1 did not significantly differ 
between COPD patients with and without pulmonary hyper-
tension. To our knowledge, there are few reports available con-
cerning the relationships between the plasma level of CRP and 
ET-1 in patients with COPD. Therefore, the purpose of this study 
was designed to investigate the degree of plasma CRP and ET-1 
levels in COPD patient with and without pulmonary hyperten-
sion. In addition, we sought to determine whether plasma levels 
of ET-1 related to that of CRP in patients with COPD.
 
MATERIALS AND METHODS
Subjects
Patient with a diagnosis of COPD, determined according to the 
American Thoracic Society (ATS) guidelines (14), were recruit-
ed from January to December 2009 in the study. The inclusion Kwon YS, et al.  •  CRP and ET-1 in COPD and Pulmonary Hypertension   
1488   http://jkms.org DOI: 10.3346/jkms.2010.25.10.1487
criteria were a history of smoking, an FEV1 (forced expiratory 
volume in 1 sec)/FVC (forced vital capacity) ratio <70%, and an 
FEV1 <80% of the predicted values. Exclusion criteria were respi-
ratory disorders other than COPD, pulmonary embolism, infec-
tious diseases, malignancy, left ventricular dysfunction, recent 
surgery, and severe endocrine, hepatic, or renal diseases. At re-
cruitment, height and weight were measured and the body mass 
index was calculated (weight [kg]/height [m
2]).
Pulmonary function test
All pulmonary function tests were evaluated using a Sensormed-
ics 2400 Unit (Sensormedics; San Diego, CA, USA) that met the 
standards of the ATS (14). Most pulmonary function tests were 
obtained on the same day as the echocardiography and/or lab-
oratory investigations. Three technically acceptable measure-
ments were performed in each patient, and highest one was in-
cluded to the analyses. Acceptable maneuvers were defined as 
those with sharp peak in the flow curve and an expiratory dura-
tion greater than six seconds. FEV1, FVC, and lung volume were 
expressed as percentage of predicted values.
Echocardiography
Echocardiography was performed using a commercially avail-
able machine (Siemens Medical Solution; Malvern, PA, USA) 
equipped with a 2.5 MHz probe. Tricuspid regurgitation flow 
was identified by color flow Doppler techniques, and the maxi-
mal jet velocity was recorded from the parasternal or apical win-
dow with the continuous wave Doppler echocardiographic probe. 
The trans-tricuspid pressure gradient (ΔP) can be calculated 
from the maximum velocity of tricuspid regurgitant jets (Vmax) 
and the simplified form of the Bernouilli equation: ΔP(mmHg)= 
Vmax (m/s)×4. An estimation of pulmonary artery pressure is 
obtained by adding an estimate of right atrial pressure to ΔP. 
Pulmonary hypertension was generally defined as a mean pul-
monary artery pressure (Ppa) greater than 25-35 mmHg with a 
normal pulmonary artery wedge pressure (15). However, the 
symposium on pulmonary hypertension suggested that a sys-
tolic pulmonary artery pressure of 35 mmHg represents the cut-
off value for pulmonary hypertension when used by Doppler 
echocardiography (16). Therefore, we have divided patients into 
those without pulmonary hypertension (systolic Ppa <35 mmHg) 
and those with pulmonary hypertension (systolic Ppa ≥35 mmHg).
C-Reactive protein
Venous blood samples were drawn into empty tubes and serum 
was obtained by centrifuging at 3,000 rpm for 15 min. The sam-
ples were stored at –70°C until analyzed. Serum high sensitive 
CRP was measured by the high sensitivity nephelometric meth-
od (Dade Behring; Marburg, Germany). The results were given 
as mg/L.
Endothelin-1
Peripheral venous blood samples were obtained from antecu-
bital vein in the patients. Serum was prepared by drawing 5 mL 
of blood into tubes containing EDTA (Becton Dickinson; Plym-
outh, UK). The plasma was obtained by centrifuging 3,000 rpm 
15 min. The supernatants were stored at -70°C until analyzed. 
ET-1 plasma level was measured by a commercially available 
sandwich enzyme-linked immunoassay (R&D systems; MN, 
USA). The results were given as pg/mL.
Statistical analysis
A statistical software package (SPSS, version 17.0; SPSS Inc; 
Chicago, IL, USA) was used for all statistical analyses. The data 
are reported as mean±SD for variables that were normally dis-
tributed. The data were expressed as the median and interquar-
tile range (IQR) for variables that were not normally distributed. 
Differences between the groups (patients with vs without pul-
monary hypertension) were analyzed using unpaired Student’s 
t test and Mann-Whitney U test. Correlation coefficients were 
calculated with the Spearman rank test. A P value of <0.05 was 
considered statistically significant.
Ethics statement
This study protocol was approved by Chonnam National Uni-
versity Hospital Institutional Review Board (CRI09047-1), and 
all subjects provided informed written consent before partici-
pation.
 
RESULTS
Clinical characteristics of the study population
The 108 patients with COPD (82 male and 26 female) partici-
pated in this study. Forty-one patients were classified as having 
Table 1. Demographic data in COPD patients without and with pulmonary hypertension
Variables
Systolic Ppa
P value
<35 mmHg ≥35 mmHg
Gender
   Male
   Female
39
11
43
15
0.405
0.660
Age (yr) 70.5±6.9 72.9±6.1 0.159
BMI (kg/m
2) 22.0±4.1 21.0±3.5 0.171
Smoking history (pack-year)   44.6±25.6   42.5±24.9 0.711
FEV1 (% predicted)   48.1±10.3   43.8±15.6 0.079
FVC (% predicted)   68.6±14.2   64.3±20.7 0.212
FEV1/FVC ratio (%)   51.9±10.7 49.5±9.5 0.232
RV (% predicted) 134.5±31.5 150.9±31.3 0.051
TLC (% predicted) 111.2±21.3 122.3±31.7 0.110
PaO2 (mmHg) 66.0±1.4 63.7±2.9 0.103
PaCO2 (mmHg) 49.4±3.2 51.4±8.8 0.179
Values are expressed as mean±SD, unless otherwise indicated.
Ppa, pulmonary artery pressure; BMI, body mass index; FEV1, forced expiratory volume 
in one second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; 
PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension.Kwon YS, et al.  •  CRP and ET-1 in COPD and Pulmonary Hypertension  
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moderate COPD (FEV1 ≥50%), 55 patients as severe COPD (30% 
≤FEV1 <50%), 12 patients as very severe COPD (FEV1 <30%) when 
stratified by ATS guidelines (15). The clinical characteristics of the 
two groups are shown in Table 1. Pulmonary hypertension was 
present in 58 patients (mean systolic Ppa, 49.4±12.9 mmHg) and 
was absent in 50 patients (mean systolic Ppa, 23.6±4.3 mmHg). 
The two groups of subjects were similar with regard to age, sex, 
smoking history (packs/year) and body mass index. Compared 
to patients without pulmonary hypertension, patient with pul-
monary hypertension had a trend toward lower FEV1 and higher 
residual volume. However, it did not reach statistical significance. 
Also, no differences were observed in blood gas analysis results 
between the two groups.
CRP and ET-1 levels in patients with and without 
pulmonary hypertension
Plasma CRP levels were significantly higher in patients with pul-
monary hypertension than in patients without hypertension 
(median, 8.0 mg/L [IQR, 3.0-13.4 mg/L] vs. median, 4.4 mg/L 
[IQR, 2.9-7.5 mg/L]; P=0.026) (Fig. 1). Plasma ET-1 levels were 
significantly higher in patients with pulmonary hypertension 
than in patients without hypertension (median, 4.1 pg/mL [IQR, 
1.9-6.6 pg/mL] vs. median, 1.7 pg/mL [IQR, 1.1-3.7 pg/mL]; P= 
0.001) (Fig. 2). There were significant positive correlations be-
tween the plasma ET-1 level and CRP level in patients with COPD 
(without or with pulmonary hypertension) (r=0.712, P=0.001) 
(Fig. 3). For COPD patients, systolic Ppa correlated significantly 
with plasma CRP levels (r=0.461, P=0.001) and plasma ET-1 lev-
els (r=0.531, P=0.001) (Fig. 4, respectively).
 
DISCUSSION
The present study demonstrated that COPD patients with pul-
monary hypertension had higher plasma CRP and ET-1 levels 
compared to those without pulmonary hypertension. In patients 
with COPD, plasma CRP and ET-1 levels correlated significantly 
with systolic pulmonary artery pressure. In addition, there were 
significant positive correlations between the plasma ET-1 level 
and CRP level in patients with COPD. These findings suggest 
that CRP and ET-1 play a role in the pathogenesis of pulmonary 
hypertension associated COPD. 
  Cigarette smoke in rats induced proliferation of cells in pul-
monary vasculature and in the airways (17). Airway inflamma-
tion, induced by chronic cigarette smoking, may lead to pulmo-
nary vascular changes. The primary regulators of CRP are inter-
leukin (IL)-6, IL-1b and a tumor necrosis factor (TNF)-α, which 
are secreted by neutrophil granulocytes and macrophages at 
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Fig. 1. Plasma levels of CRP in COPD patients without and with pulmonary hyperten-
sion. There is significant difference between the two groups (P=0.026). Plasma CRP 
levels are expressed as the median and interquartile range. 
●, outlier extending >1.5 box-lengths from the edge of the box; Ppa, pulmonary artery 
pressure; CRP, C-reactive protein.
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Fig. 2. Plasma levels of ET-1 in COPD patients without and with pulmonary hypertension. 
There is significant difference between the two groups (P=0.001). Plasma ET-1 levels 
are expressed as the median and interquartile range. 
●, outlier extending >1.5 box-lengths from the edge of the box; Ppa, pulmonary artery 
pressure; ET-1, endothelin-1.
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Fig. 3. The relationship between plasma levels of ET-1 and CRP in this study. There 
is significant correlation between ET-1 and CRP levels (P=0.001). 
CRP, C-reactive protein; ET-1, endothelin-1.
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sites of injury. Inflammatory cytokines such as IL-6 and TNF-α 
are markers of elevated pulmonary artery pressure in COPD (6, 
7). A recent study demonstrated that CRP levels correlated with 
pack-years of smoking and predicted all-cause mortality in pa-
tients with mild to moderate COPD (18). In COPD patients with 
pulmonary hypertension, serum CRP level was higher compared 
to those without pulmonary hypertension (6). Our data demon-
strated that plasma CRP levels were significantly higher in patient 
with pulmonary hypertension compared to those without hy-
pertension. In addition, we found positive correlations between 
plasma levels of CRP and systolic pulmonary arterial pressure. 
These results suggested that systemic inflammation might be 
related to pulmonary hypertension in patient with COPD. How-
ever, a recent study in patients with moderate to very severe COPD 
showed that there was no relationship between CRP levels and 
likelihood of survival (19). Further long-term studies are needed 
to address the physiological role and clinical outcome of CRP in 
COPD patients with pulmonary hypertension.
  ET-1 is a vasoactive mediator that causes vasoconstriction 
and vascular wall proliferation. Therefore, ET-1 has been sug-
gested that ET-1 may contribute to increases in pulmonary ar-
terial tone or smooth muscle proliferation in patients with pul-
monary hypertension. Immunocytochemical analysis of lung 
specimen demonstrated that pulmonary hypertension was as-
sociated with the increased expression of ET-1 in vascular endo-
thelial cells (20). Furthermore, there is a significant correlation 
between pulmonary ET-1 concentration and pulmonary vascu-
lar resistance (21). Our findings confirm these observations (20, 
21) by showing that plasma ET-1 level was significantly higher in 
patient with pulmonary hypertension than in patients without 
hypertension. In addition, a significant relationship was observ-
ed between ET-1 level and systolic pulmonary artery pressure. 
These evidences suggest that ET-1 may result in remodeling of 
the pulmonary vasculature, leading to the development of pul-
monary hypertension in patients with COPD. However, our re-
sults are based on single measurements of CRP, ET-1 and pul-
monary artery pressure, which may not reflect these relation-
ships over time. Therefore, this study does not provide informa-
tion about the time-course relationship between CRP and ET-1 
and pulmonary hypertension. Several reports of ET-1 levels in 
COPD patients with pulmonary hypertension have been con-
flicting (13, 22). Fujii et al. (22) showed that there was no corre-
lation between the plasma ET-1 level and pulmonary artery pres-
sure. Further studies are necessary to elucidate these conflict-
ing results.
  ET-1 is also thought to have a proinflammatory effect in the 
airways, being both a chemoattractant and upregulator of other 
inflammatory mediators, such as IL-6 and IL-8 (25). Subsequent-
ly, IL-6 and IL-8 stimulate the production of CRP in the liver. ET-1 
levels are found elevated in several pulmonary disease such as 
asthma (24, 25), COPD (22), and idiopathic pulmonary fibrosis 
(26). These pulmonary diseases are associated with inflamma-
tory response, characterized by increased CRP levels. Several 
studies (27, 28) have shown that both ET-1 and CRP are implicat-
ed in the inflammatory process of cardiovascular diseases. Wang 
et al. (27) demonstrated that ET-1 induces CPR production in 
rat vascular smooth muscle cells. On the other hand, Gemici et 
al. (29) showed that there was no correlation between the plas-
ma levels of ET-1 and CRP in coronary artery disease. However, 
there are few reports available concerning the relationships be-
tween the plasma level of CRP and ET-1 in patients with COPD. 
We found out that there was a significant positive correlation 
between plasma ET-1 and CRP levels in the COPD patients. This 
finding supports a concept of the link between plasma CRP and 
ET-1 in patients with COPD. 
  In conclusions, our study demonstrated that pulmonary hy-
pertension in patients with COPD were associated with higher 
plasma CRP and ET-1 level. In addition, plasma levels of CRP 
ET-1 (pg/mL)
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Fig. 4. The relationship between systolic Ppa and plasma CRP levels (A) and ET-1 levels (B). Systolic Ppa correlate significantly with plasma CRP levels (r=0.461, P=0.001) and 
serum ET-1 levels (r=0.531, P=0.001). 
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and ET-1 were significantly correlated with systolic pulmonary 
artery pressure in patient with COPD. These findings support a 
possibility that CRP and ET-1 correlate to pulmonary hyperten-
sion in COPD patients. Further investigations are necessary to 
reveal the pathophysiological role of systemic inflammation in 
the pulmonary hypertension associated with COPD patients.
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